SWOG Update
April 2010

all-in-one page for printing
Contents  
Welcome to the April 2010 SWOG Update.

For all members and friends of the Southwest Oncology Group, the SWOG Update will keep you informed of what's happening with the Group. News to report? Send it to communications@swog.org.

View a one-page version for printing.
 
Study Updates  
S0941: TKIs against biliary cancers
bile ducts illustration Just launched, S0941 tests combined erlotinib and sorafenib on patients with unresectable or metastasized gallbladder carcinoma or cholangiocarcinoma. [more]
 

SPOTLIGHT

SWOG cancer trials network awarded $120+ million in competitive renewal of NCI grants

Dr. Anne Schott at podium announcing renewal of grant
The award was announced at an April 9, 2010 press briefing by Group Executive Officer Anne F. Schott, M.D. (above, at the briefing), and Michigan Congressman John Dingell. "The Southwest Oncology Group's research saves mothers, fathers, sons and daughters, and we all benefit from them getting additional investment to do more of their fine work," Dingell said in a statement. Photo: SWOG
Noting that the organization's research "has touched the lives of virtually every adult cancer patient in this nation," the National Cancer Institute (NCI) Cancer Therapy Evaluation Program has renewed the Southwest Oncology Group's treatment grants for six years, with a total funding package over that period expected to exceed $120 million.

"We're proud to be first among the ten NCI cooperative groups to embrace -- and to be funded for -- comparative effectiveness research as part of our mission," says SWOG Group Chair Laurence H. Baker, D.O., referring to recent Group initiatives to develop more formal methods of identifying which studies will have the greatest clinical benefit.

The principal grant, more than $63 million, will be administered by the University of Michigan Medical School, where SWOG is headquartered, and is the largest single research award ever to that school. Most of the remainder of the NCI package will be distributed directly to the Group's member institutions, including twelve U10 grants to core members.

The eighteen-month competitive renewal process that preceded the award involved a rigorous review of all SWOG activities, committees, and U10 institutions. NCI's Sub-committee H, which reviewed the grant application, praised the Group's "outstanding record of productivity," citing the more than 300 peer-reviewed publications that document SWOG trial results during the previous five-year grant cycle.

The grant package supports the Group's Ann Arbor headquarters, its operations office in San Antonio, and its statistical center in Seattle. But the majority of the funds go to member institutions nationwide, helping them defray the cost of bringing patients into clinical trials and supporting investigators leading those trials.



Administrata

Speeding the protocol and contract development process

-- by Nathan Eriksen, SWOG chief of administration

Nathan Eriksen, SWOG chief of administration
Photo: SWOG
We recently submitted a proposal to the National Cancer Institute in response to their RaPID grant request for applications. The RaPID program is meant to support cooperative group efforts to speed the process of protocol and contract development and implementation in line with the NCI Operational Efficiency Working Group's (OEWG's) recommendations.

The need for a shorter timeline for protocol development is one SWOG has understood, and has been addressing, for some time. Our SWAT process, which applies additional resources to ushering through high priority protocols on an accelerated development schedule, was rolled out initially in 2008.


Our competitive renewal process has just come to fruition, and when it was submitted a year ago we outlined our plan for many of the steps detailed below. When it comes to improving efficiency, our Group Chair, Dr. Baker, has been driving us toward change for some time. The OEWG recommendations and the RaPID program provide us additional input from the NCI to add to our own evaluations, give us a chance to align our tactics with those of the Institute, and (we hope) will bring us some badly needed funding to help implement our initiatives.

Our RaPID proposal outlines the steps we plan to take, including the following elements:
  • Hire a contracting specialist
    A new contracting specialist will help ensure that protocols and contracts move through the many review cycles in the development process according to an ambitious timeline.

    Study coordinators and protocol coordinators oversee all aspects of protocol development. The contracting specialist will focus on two aspects: timeline and contracting.

  • Upgrade existing protocol development tracking tool
    For several years, the protocol development team in the Operations Office has used an online tracking tool to track the process. We will enhance this tool in several ways, including adding a function that will automatically send reminder e-mails to reviewers when a deadline is approaching or has passed. We will also add Web-based tracking reports for those involved in the process.

  • Add a contract development tracking tool
    We're developing a module that will integrate the tracking of the contracts and protocol related grant applications along with the protocol itself.

  • Consultant to help improve adoption of the CIRB
    Garnering protocol approval by local Institutional Review Boards (IRBs) can be a lengthy undertaking, delaying initial activation of a trial at many sites, not to mention interrupting ongoing trial accrual as protocol amendments await approval.

    The National Cancer Institute's Central IRB (CIRB) was established to speed this process, replacing numerous individual reviews with one central review that could allow many sites to expedite their review. To date, though, most SWOG sites don't take advantage of the CIRB, still relying instead on review by their local IRB.

    Our RaPID proposal will bring in a consultant to help us better understand why many of SWOG's high-accruing institutions haven't switched to CIRB review and help encourage and facilitate that switch. Reducing the time to activation benefits individual sites as well as the Group as a whole. We need to do a better job of helping sites recognize these benefits.

Our RaPID proposal embraces the recommendations of the OEWG and lays out a plan that will, along with the dedicated effort of many individuals within the Group, allow us to meet their aggressive timelines.

When it comes to reducing the time between protocol concept and trial activation, we are focused on and dedicated to continuing improvement.

Administrata is an occasional column by Nathan Eriksen, chief of administration for the Southwest Oncology Group.

protocol and contract development timeline



Study Update

S0941: New study uses tyrosine kinase inhibitors against biliary cancers

Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma

diagram highlighting gall bladder, pancreas, and associated ducts
Credit: NCI
Cancer of the bile ducts or gallbladder is diagnosed in almost 10,000 new patients each year in the U.S., according to American Cancer Society figures.

For patients whose biliary cancer is unresectable or has metastasized, cytotoxic chemotherapy generally has limited effect, resulting in mean survival times of less than a year. Gemcitabine-based chemo is the one used most frequently, and the gemcitabine and cisplatin combination is one standard option, based on the results of a recent phase II study showing an overall survival of 11 months and progression-free survival of 8 months with this combination.

This modest success with chemotherapy has turned more recent research efforts toward better understanding the molecular origins of biliary cancers, leading to the identification of promising molecular targets for therapy, including vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR).

In one recent study, more than half of 236 cases of cholangiocarcinoma showed overexpression of VEGF, and almost one quarter of the cases showed overexpression of EGFR. VEGF expression showed an association with metastasis, and EGFR expression an association with tumor progression.

The newly launched S0941 aims for both targets, combining a VEGF pathway inhibitor -- sorafenib -- with an EGFR inhibitor -- erlotinib. Therapies combining tyrosine kinase inhibitors to target both VEGF and EGFR pathways simultaneously have shown significant clinical activity in colon cancer and other tumor types.

"The cross-talk between the EGFR and VEGF pathways lends theoretical support to combining two agents that target these pathways," says study coordinator Anthony B. El-Khoueiry, M.D., of the University of Southern California's Norris Cancer Center. "This study builds on the previous SWOG S0514 study of sorafenib alone in cholangiocarcinoma as well as on a study of erlotinib alone in the same patient population."

S0941 patients will take 100 mg of oral erlotinib each day and 400 mg of oral sorafenib twice a day until their disease progresses or drug toxicity becomes unacceptable. They will be followed for up to three years.

The primary objective will be progression-free survival, with overall survival as a secondary objective in patients with advanced biliary cancers who have not had any prior therapy for metastatic or unresectable disease. The study also seeks to assess the response rate and the frequency and severity of toxicities.

Eligibility
Patients with a confirmed diagnosis of either gallbladder carcinoma or cholangiocarcinoma with disease that is unresectable or metastatic may be eligible. Disease should be measurable and confirmed cytologically or pathologically. Patients with ampullary carcinoma are not eligible. Patients must not have received any prior therapy for metastatic disease. The study accrual target is 50 patients. Please review the detailed eligibility criteria.

Eligible patients can find the nearest participating institution online or by contacting the Southwest Oncology Group at (210) 614-8808 or at protocols@swog.org.



SELECT Biorepository Symposium, May 4

SELECT trial logo
As the largest prostate cancer prevention trial ever undertaken, the Selenium and Vitamin E Cancer Prevention Trial, or SELECT, has assembled a substantial biorepository of specimens.

To help make SELECT resources available to a wider research community, the Southwest Oncology Group (SWOG) has issued a call for participation in a May 4, 2010, symposium in Dallas to develop an RFP for projects using this biorepository. The symposium will bring together leaders in the major research areas of SELECT to discuss the state of science and outline potential future directions.

Investigators interested in participating should complete the brief application form at swog.org/select.

SELECT is an NCI-funded phase III study of the effects of selenium and vitamin E, both separately and together, on the incidence of prostate cancer. The study opened in 2001 and quickly accrued 35,533 men. In the fall of 2008, the trial's Data and Safety Monitoring Committee recommended that participants discontinue taking study supplements based on an interim finding of no preventive benefit. The almost 31,000 participants remaining on SELECT are now being transitioned to a centralized follow-up system to track their health.

The trial's growing biorepository of specimens includes toenail clippings, baseline and post-baseline blood draws, linked nutritional data, adherence cohort data, and a vast clinical database from semiannual visits with each participant.

It also holds prostate biopsies and surgical specimens collected from a subset of the more than 2,100 men who have been diagnosed with prostate cancer during the course of the trial. DNA has been extracted from the serum of these prostate cancer patients and from an age- and race-matched cohort of controls.



Funding for correlative studies from multi-site trials

A reminder that the National Cancer Institute has two grant programs to support correlative studies that use specimens from multi-site trials (qv the SELECT Biorepository story):

Ian Thompson named director of CTRC

Ian Thompson, Jr., M.D. The Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio, which formerly housed the Southwest Oncology Group, has named Ian Thompson, Jr., M.D., to the permanent position of executive director. Thompson served as interim executive director of the CTRC for the previous five months. He is chair of SWOG's Genitourinary Committee.

CRA Openings (Spring 2010)

-- by Amy DeBlaise, B.A., C.C.R.P., Communications Chair, CRA Committee

Have you ever wanted to see your name in the Group Meeting guide or in the Report of Studies? Do you wonder how to become active in a Disease Site Committee? Well, you have your chance right now. The CRA Executive Committee is asking interested and dedicated Clinical Research Associates to self-nominate for open CRA Committee positions. Positions are available on the following committees:
  1. Cancer Prevention Committee (1 position)
  2. Symptom Control and QOL Committee (1 position)
  3. Health Disparities and Outcomes Committee (1 position)
  4. Molecular Epidemiology Committee (Disease Site representative needed for the following)
    • Bone Marrow/Stem Cell
    • Early Therapeutics
    • Pharmacy
    • Surgery
    • Translational Medicine
    • Clinical Practices
As a Committee Representative you may be asked to participate in protocol reviews, serve as a resource to other CRAs, or perform other duties as assigned.

If you are interested in self-nominating or would like more information, please contact Amy DeBlaise, B.A., C.C.R.P., communications chair, at amy.deblaise@CHW.edu or at 818-409-7653 during normal business hours PST.

Self-nominations are contingent on supporting documentation from your PI and a telephone interview.



Handling pharmaceuticals: Training video available

To all CRAs:

Please take some time to review this online Pharmacy Training program. It provides valuable update information which will help reinforce proper investigational drug handling and drug accountability.



Untitled Document

Recent and Upcoming SWOG Abstracts

ABSTRACTS

Presented

S0000

Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial. E Cook, K Arnold, J Hermos, W McCaskill- Stevens, S Moody-Thomas, J Probstfield, SJ Hamilton, R Campbell, K Anderson, L Minasian. NCI-ASCO Cancer Trial Accrual Symposium: Science and Solutions (April 29-30, 2010, Bethesda, MD); poster presentation.

S0000

Infrastructure for successful recruitment when conducting a multi-site clinical trial: the SELECT experience. KB Anderson, ED Cook, SJ Hamilton, LM Minasian, JA Hermos, JL Probstfield. NCI-ASCO Cancer Trial Accrual Symposium: Science and Solutions (April 29-30, 2010, Bethesda, MD); poster presentation.

S0000

S0000 The role of a community based organization in a large prevention trial. SJ Hamilton, ED Cook, KB Anderson, JQ Sheats. NCI-ASCO Cancer Trial Accrual Symposium: Science and Solutions (April 29-30, 2010, Bethesda, MD); poster presentation.

S0727

Phase I trial of combination gemcitabine, erlotinib (NSC-718781), and IMC-A12 (NSC-742460) as first-line treatment in patients with metastatic pancreatic cancer: Southwest Oncology Group study S0727. PA Philip, BH Goldman, RK Ramanathan, H Lenz, AM Lowy, RP Whitehead, S Iqbal, VM Chung, JK Benedetti, CD Blanke. 2010 Gastrointestinal Cancers Symposium (January 22-24, 2010, Orlando, FL), abst. #233 (poster).

Accepted

S8814

Potential tumor biologic causes of the racial survival disparity in ER-positive breast cancer adjuvant trials. KS Albain, WE Barlow, S Shak, GN Hortobagyi, DF Hayes. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted for oral presentation.

S9304

Intratumoral gene expression levels of TP (Thymidine phosphorylase)) and VEGF are associated with clinical outcome in stage II/III rectal cancer patients treated with 5-fluorouracil (5-FU) and pelvic radiation in a phase III intergroup trial (SWOG 9304). R Ladner, CM Ulrich, C Rankin, K Danenberg, P Danenberg, S Smalley, K Makar, J Benedetti, CD Blanke, HJ Lenz. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

S9917

Southwest Oncology Group (SWOG) trial S9917: randomized phase 3 trial of selenium supplementation to prevent prostate cancer among men with high grade prostatic intraepithelial neoplasia (HGPIN). JR Marshall, CM Tangen, WA Sakr, DP Wood, SM Lippman, D Jarrad, DS Alberts, DL Berry, ED Crawford, IM Thompson. American Urological Association Annual Meeting (May 29-June 3, 2010, San Francisco, CA); accepted for oral presentation.

S9921

Southwest Oncology Group study 9921: prolonged event free survival in high risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. IM Thompson, B Ely, CM Tangen, MHA Hussain, DP Wood, GP Swanson, DI Quinn, TB Dorff, NA Dawson, NB Haas, ED Crawford. American Urological Association Annual Meeting 2010 (May 29-June 3, 2010, San Francisco, CA); accepted for oral presentation.

S0000

Impact of supplemental site grants to increase African American accrual for the selenium and vitamin e cancer prevention trial. E Cook, K Arnold, J Hermos, W McCaskill- Stevens, S Moody-Thomas, J Probstfield, S Hamilton, R Campbell, K Anderson, L Minasian. Society of Clinical Trials 2010 Annual Meeting (May 16-19, 2010, Baltimore, MD), accepted as poster presentation.

S0000

Video productions in SELECT: effective tools for staff learning and participant motivation in clinical trials. JM Harris- Talley, D Arney, K Anderson, JA Hartline. Society for Clinical Trials 2010 Meeting (May 16-19, 2010, Baltimore, MD), accepted as poster presentation.

S0000

Effect of vitamin E and selenium on incidence of physician- diagnosed COPD: the selenium and vitamin E cancer prevention trial (SELECT). PA Cassano, KB Arnold, K Guertin, AR Kristal, JJ Crowley JA Hartline, PJ Goodman, CM Tangen, LM Minasian, SM Lippman, CA Coltman, E Klein. American Thoracic Society 2010 Annual Meeting May 14-19, 2010, New Orleans, LA); accepted for oral presentation.

S0008

Should unknown primary melanomas be excluded from adjuvant therapy trials? Insights from the SWOG S0008 phase III randomized adjuvant trial. VK Sondak, R Tuthill, J Moon, JA Thompson, C Lao, B Redman, LE Flaherty. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

S0008

Minimal residual disease (MRD) in peripheral blood (PB) assessed prospectively by RT-PCR for melanoma- associated genes is an independent prognostic factor for survival in stage III melanoma (Mel) patients (pts) enrolled onto an intergroup adjuvant trial S0008. JA Sosman, J Moon, PY Liu, L Flaherty, MB Atkins, KA Margolin, J Kirkwood, V Sondak, for SWOG and ECOG. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

S0028

Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced (adv) urothelial cancer (UC), aged > 70 years (yrs): SWOG 0028. D Raghavan, C Tangen, C Moinpour, C Gotay, K Albain, S Louie, H-J Lenz, D Quinn, M Hussain, I Thompson. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

S0329

A phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study. KE Bickel, J Moon, O Kucuk, RH Wheeler, S Urba, G Wolf, FP Worden. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted for poster presentation.

S0421

Circulating tumor cell capture and analysis in a multi- center SWOG-coordinated prostate cancer trial. A Goldkorn, T Xu, B Lu, A Williams, LM Fink, CM Tangen, Y-C Tai, DI Quinn, P Twardowski, RJ Cote. American Society for Clinical Oncology, 2010 Annual Meeting,TIP (“Trials in Progress”) [June 4-8, 2010, Chicago, IL]; accepted as poster presentation.

S0430

Simple oral therapy with capecitabine (CAPE) and cyclophosphamide (CPA) for metastatic breast cancer (MBC). AF Schott, D Lew, WE Barlow, KS Albain, HK Chew, JL Wade, KS Lanier, HM Linden, GN Hortobagyi, RB Livingston. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted for oral presentation.

S0438

Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group trial S0438. K Margolin, J Moon, L Flaherty, C Lao, W Akerley, J Sosman, J Kirkwood, V Sondak. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted for oral presentation.

S0727

A randomized phase II trial of combination gemcitabine + erlotinib + IMC-A12 (cixutumumab) vs. gemcitabine + erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer: Southwest Oncology Group study (SWOG S0727). PA Philip, B Goldman, RK Ramanathan, HJ Lenz, AM Lowy, RP Whitehead, S Iqbal, V Chung, JK Benedetti, CDBlanke. American Society for Clinical Oncology, 2010 Annual Meeting, TIP (“Trials in Progress”) [June 4-8, 2010, Chicago, IL]; accepted as poster presentation.

E2205

A phase II study to measure response rate and toxicity of neoadjuvant chemoradiotherapy with oxaliplatin (OX) and infusional 5-fluorouracil (5-FU) plus cetuximab followed by post-operative docetaxel cetuximab in patients with operable adenocarcinoma of the esophagus. MK Gibson, L Kleinberg, C Staley, P Catalano, F Song, MF Mulcahy, LP Leichman, AB Benson. American Society for Clinical Oncology, 2010 Annual Meeting (June 4-8, 2010, Chicago, IL); accepted as poster presentation.

4B951

Cell cycle regulatory protein alterations in a randomized clinical trial of adjuvant chemotherapy following radical cystectomy and pelvic lymphadenectomy. S Lerner, W Stadler, S Groshen, J Cai, A Mitra, E Tuazon, D Skinner, D Raghavan, D Esrig, G Steinberg, C Hall, R Cote. American Urological Association Annual Meeting 2010 (May 29-June 3, 2010, San Francisco, CA); accepted as poster presentation.



New SWOG sites

SWOG member institution the University of Utah has added a new network component site, the Dixie Regional Medical Center.

SWOG also has two new affiliate institutions:

  • Lahey Clinic Medical Center
    PI: Paul J. Hesketh, M.D.
    Head CRA: Julie C. Roache, B.S.

  • University of Florida Shands Cancer Center in Gainesville, FL
    PI: Nam H. Dang, M.D., Ph.D.
    Head CRA: Giselle Moore-Higgs, A.R.N.P.

Finally, the Kansas City CCOP has added two new institutions as network component sites:

  • Heartland Hematology-Oncology Associates, Inc., Kansas City, MO

  • Liberty Radiation Oncology Clinic, Liberty, MO

And a correction
The March Update listed two new SWOG institutions -- St Mary's Hospital in Grand Junction, CO and St Francis Hospital and Medical Center in Hartford, CT -- but mistakenly associated the wrong names with these sites.

Sue Majeski, C.C.R.P., of the University of Colorado, writes of St. Mary's Hospital "I am working with Diane Melancon, M.D., and Mary Vaughan, R.N., to get Grand Junction up and running."

St. Francis Hospital and Medical Center is a network component for the Michigan CRC CCOP, whose head CRA, Beth LaVasseur, R.N., M.S., identifies Jonathon Sporn, M.D., and Carla Mancini, R.N., B.S.N., as the investigator and CRA responsible for St. Francis.



Protocol cards help keep up awareness of trials

They were everywhere at the San Francisco meeting -- postcard-sized overviews of eligibility criteria and schema for trials S0702 and S0337.

The first of a set of cards printed to help raise awareness of selected trials, they are designed to serve as a quick, handy tool to help with initial screening of a potential trial participant. They fit easily in a lab coat pocket and include contact information if you have questions about a study.

If you didn't pick up any in San Francisco, SWOG will be mailing copies to sites where these trials are active.

protocol cards for S0702 and S0337



New SWOG slide template available

new template for SWOG slide
For those of you who were covetously eyeing the slide layout Dr. Baker used in his plenary presentation in San Francisco, the template is available for download by members.

A new, cleaner look for SWOG presentations, the design picks up elements from the SWOG logo and colors from the SWOG Web site. You will see the look reflected in the design of a number of newly printed items from the Southwest Oncology Group in coming months.



Some like it hot. But not biospecimens.

A reminder from the SWOG Data Operations Center to all who send specimens to the lymphoma and myeloma repositories at the University of Arizona. Daily temperatures from spring to fall in Arizona are above 95 degrees. All samples -- draw tubes, aliquotted but not yet frozen serum, bone marrow, slides, and paraffin blocks -- must have cold packs. U.S. mail is not the preferred method as their delivery time is often too long and the integrity of the blocks and slides this time of year is often compromised.

All frozen samples should contain a minimum of 5 pounds of dry ice to ensure sample integrity throughout the duration of shipment.



CALGB's new Specimen Tracking System (STS) takes off

For those who put patients on trials for the Cancer and Leukemia Group B, that cooperative group has just deployed a new system for tracking specimens. Benefits of CALGB's Specimen Tracking System (STS) include the following:
  • Easy to use Web-based system
  • Specimen Checklist clearly shows which specimens to collect when
  • No more paper specimen submission forms
  • Better communication between collecting sites and repositories and laboratories
  • Self-paced training, recorded Webinar, and User Guide available online
The system also includes on-screen instructions, one-click lookup for specimen preparation and shipping instructions, and automatically generated packing slips. Learn more about the new CALGB STS from the system's help menu.
CALGB Specimen Tracking System

Resource for adolescent and young adult (AYA) cancers on NCI site

In summer 2009 the NCI held a workshop titled "Unique Characteristics of AYA Cancers: Focus on ALL, Breast Cancer and Colon Cancer."

Presentations from that workshop are available as resources on the CTEP Web site.



Looking for talent? Try SWOG

help wanted sign

Got a SWOG-related position to fill? Post it where your fellow SWOG members can see it: right here.

The SWOG Update will list your postings for positions related to clinical trials.

Just e-mail communications@swog.org with the position's

  • title
  • location
  • degree(s) required
  • full-time/part-time status
  • link to more information

SWOG encompasses a wealth of talent. Let's keep it in the Group.

 

Listings

  • Chief of the Section of Hematology/Oncology, University of Oklahoma Health Sciences Center
    The consultant on this search refers to this position as "a great building opportunity for a seasoned cancer leader. In addition to expanding the capabilities of the section in the Department of Medicine, the incoming Section Chief will hold an administrative role in the Oklahoma Cancer Institute. Construction is currently underway for a new, fully-integrated cancer center, which will provide the opportunity for the division to expand both clinical services and basic, translational and clinical research. The OU Cancer Institute is pursuing NCI designation as a Comprehensive Cancer Center."

    http://www.oumedicine.com/landing.cfm?id=633

    Information about the OU Cancer Institute can be found at http://www.oumedicine.com/academictemplate_landing.cfm?id=90 and at http://www.oumedicine.com/body.cfm?id=295.

    Contact:
    Trisha Chogich
    Senior Associate
    Alexander, Wollman & Stark
    (703) 973-7623

  • Serious Adverse Events Program Manager and Nurse Auditor, SWOG Operations Office, San Antonio, TX
    Oversees and manages the centralized reporting process for serious adverse events on oncology research trials. Also responsible for conducting quality assurance audits according to GCP guidelines for the Southwest Oncology Group. RN with clinical research experience required. BSN degree with minimum three years oncology nursing experience preferred. Must have strong organizational, verbal, and written communication skills. Must be willing to travel up to 25%. Fax resume to (210) 614-0006. EOE/AA. Learn more.





Got news to tell? Send it to communications@swog.org.